guest ::
| Home > Publications database > Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease models. > print |
| Home > Publications database > Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease models. > print |
| 001 | 304510 | ||
| 005 | 20251117100721.0 | ||
| 024 | 7 | _ | |a 10.1172/JCI169395 |2 doi |
| 024 | 7 | _ | |a pmid:40932790 |2 pmid |
| 024 | 7 | _ | |a 0021-9738 |2 ISSN |
| 024 | 7 | _ | |a 1558-8238 |2 ISSN |
| 024 | 7 | _ | |a altmetric:181558667 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2025-01898 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Crouchet, Emilie |b 0 |
| 245 | _ | _ | |a Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease models. |
| 260 | _ | _ | |a Ann Arbor, Mich. |c 2025 |b ASCJ |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1763370403_1699446 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2025 Sep 11;135(21):e169395 |
| 520 | _ | _ | |a Treatment options for advanced liver disease and hepatocellular carcinoma (HCC) are limited and strategies to prevent HCC development are lacking. Aiming to discover novel therapeutic targets, we combined genome wide transcriptomic analysis of liver tissues from patients with advanced liver disease and HCC and a cell-based system predicting liver disease progression and HCC risk. Computational analysis predicted peroxiredoxin 2 (PRDX2) as a candidate gene mediating hepatocarcinogenesis and HCC risk. Analysis of HCC patient tissues confirmed a perturbed expression of PRDX2 in cancer. In vivo perturbation studies in mouse models for MASH driven hepatocarcinogenesis showed that specific Prdx2 knockout in hepatocytes significantly improved metabolic liver functions, restored AMPK activity and prevented HCC development by suppressing oncogenic signaling. Perturbations studies in HCC cell lines, a CDX mouse model and patient-derived HCC spheroids unraveled that PRDX2 also mediates cancer initiation, cancer cell proliferation and survival through its antioxidant activity. Targeting PRDX2 may therefore be a valuable strategy to prevent HCC development in metabolic liver disease. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Carbohydrate metabolism |2 Other |
| 650 | _ | 7 | |a Hepatology |2 Other |
| 650 | _ | 7 | |a Oncology |2 Other |
| 650 | _ | 7 | |a Preventative medicine |2 Other |
| 650 | _ | 7 | |a Therapeutics |2 Other |
| 700 | 1 | _ | |a Schaeffer, Eugénie |b 1 |
| 700 | 1 | _ | |a Oudot, Marine A |b 2 |
| 700 | 1 | _ | |a Moehlin, Julien |b 3 |
| 700 | 1 | _ | |a Gadenne, Cloé |b 4 |
| 700 | 1 | _ | |a Jühling, Frank |b 5 |
| 700 | 1 | _ | |a El Saghire, Hussein |b 6 |
| 700 | 1 | _ | |a Fujiwara, Naoto |b 7 |
| 700 | 1 | _ | |a Zhu, Shijia |b 8 |
| 700 | 1 | _ | |a Akter Rasha, Fahmida |b 9 |
| 700 | 1 | _ | |a Durand, Sarah C |b 10 |
| 700 | 1 | _ | |a Charlot, Anouk |b 11 |
| 700 | 1 | _ | |a Ponsolles, Clara |b 12 |
| 700 | 1 | _ | |a Martin, Romain |b 13 |
| 700 | 1 | _ | |a Brignon, Nicolas |b 14 |
| 700 | 1 | _ | |a Del Zompo, Fabio |b 15 |
| 700 | 1 | _ | |a Meiss Heydmann, Laura |b 16 |
| 700 | 1 | _ | |a Parnot, Marie |b 17 |
| 700 | 1 | _ | |a Hamdane, Nourdine |b 18 |
| 700 | 1 | _ | |a Heide, Danijela |0 P:(DE-He78)92c93319837b4b915db8393795faf0b6 |b 19 |u dkfz |
| 700 | 1 | _ | |a Hetzer, Jenny |0 P:(DE-He78)9c964482bd7f3f66d88f99962e175f39 |b 20 |u dkfz |
| 700 | 1 | _ | |a Heikenwälder, Mathias |0 P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5 |b 21 |u dkfz |
| 700 | 1 | _ | |a Felli, Emanuele |b 22 |
| 700 | 1 | _ | |a Pessaux, Patrick |b 23 |
| 700 | 1 | _ | |a Pochet, Nathalie |b 24 |
| 700 | 1 | _ | |a Zoll, Joffrey |b 25 |
| 700 | 1 | _ | |a Cunniff, Brian |b 26 |
| 700 | 1 | _ | |a Hoshida, Yujin |b 27 |
| 700 | 1 | _ | |a Mailly, Laurent |b 28 |
| 700 | 1 | _ | |a Baumert, Thomas F |b 29 |
| 700 | 1 | _ | |a Schuster, Catherine |b 30 |
| 773 | _ | _ | |a 10.1172/JCI169395 |0 PERI:(DE-600)2018375-6 |n 21 |p e169395 |t The journal of clinical investigation |v 135 |y 2025 |x 0021-9738 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:304510 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 19 |6 P:(DE-He78)92c93319837b4b915db8393795faf0b6 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 20 |6 P:(DE-He78)9c964482bd7f3f66d88f99962e175f39 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 21 |6 P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J CLIN INVEST : 2022 |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2024-02-16T10:37:49Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2024-02-16T10:37:49Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Peer review |d 2024-02-16T10:37:49Z |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2024-02-16T10:37:49Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-27 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-27 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-27 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b J CLIN INVEST : 2022 |d 2024-12-27 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2024-12-27 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2024-12-27 |
| 920 | 1 | _ | |0 I:(DE-He78)D440-20160331 |k D440 |l Chronische Entzündung und Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D440-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|